{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T14:01:57Z","timestamp":1790863317490,"version":"4.1.0"},"reference-count":72,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2025,1,18]],"date-time":"2025-01-18T00:00:00Z","timestamp":1737158400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>In this narrative review, we explore the burden and risk factors of various herpesvirus infections in patients receiving chimeric antigen receptor T-cell (CAR-T) therapy or bispecific antibodies (BsAb) for the treatment of hematologic malignancies. Antiviral prophylaxis for herpes simplex\/varicella zoster viruses became part of the standard of care in this patient population. Breakthrough infections may rarely occur, and the optimal duration of prophylaxis as well as the timing of recombinant zoster immunization remain to be explored. Clinically significant cytomegalovirus (CMV) infections can affect up to 10% of patients after CAR-T, depending on the CAR-T product target, post-CAR-T complications such as cytokine release syndrome and the need for glucocorticoid therapy. Surveillance and prophylactic strategies for CMV need to be developed, whereas the risk factors for and the burden of CMV infections after BsAb are not yet well-defined. Human herpes virus 6 reactivation and end organ disease such as encephalitis are rarely reported after CAR-T and have not yet been reported after BsAb; additional research is needed.<\/jats:p>","DOI":"10.3390\/v17010133","type":"journal-article","created":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T04:04:12Z","timestamp":1737345852000},"page":"133","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Herpesvirus Infections After Chimeric Antigen Receptor T-Cell Therapy and Bispecific Antibodies: A Review"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8730-8929","authenticated-orcid":false,"given":"Joseph","family":"Sassine","sequence":"first","affiliation":[{"name":"Infectious Diseases Section, Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily A.","family":"Siegrist","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, OU. Health, Oklahoma City, OK 73104, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roy F.","family":"Chemaly","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Infection Control, and Employee Health, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,1,18]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.cmi.2024.06.020","article-title":"Advances and prospect in herpesviruses infections after haematopoietic cell transplantation: Closer to the finish line?","volume":"31","author":"Sassine","year":"2024","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1182\/blood-2017-07-793760","article-title":"Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy","volume":"131","author":"Hill","year":"2018","journal-title":"Blood"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Vora, S.B., Waghmare, A., Englund, J.A., Qu, P., Gardner, R.A., and Hill, J.A. (2020). Infectious Complications Following CD19 Chimeric Antigen Receptor T-cell Therapy for Children, Adolescents, and Young Adults. Open Forum Infect. Dis., 7.","DOI":"10.1093\/ofid\/ofaa121"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1093\/cid\/ciy152","article-title":"Cytokine Release Syndrome Grade as a Predictive Marker for Infections in Patients with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia Treated with Chimeric Antigen Receptor T Cells","volume":"67","author":"Park","year":"2018","journal-title":"Clin. Infect. Dis."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Wudhikarn, K., Palomba, M.L., Pennisi, M., Garcia-Recio, M., Flynn, J.R., Devlin, S.M., Afuye, A., Silverberg, M.L., Maloy, M.A., and Shah, G.L. (2020). Infection during the first year in patients treated with CD19 CAR T cells for diffuse large B cell lymphoma. Blood Cancer J., 10.","DOI":"10.1038\/s41408-020-00346-7"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1182\/bloodadvances.2020002732","article-title":"Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma","volume":"5","author":"Baird","year":"2021","journal-title":"Blood Adv."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1080\/17474086.2022.2063833","article-title":"Managing hypogammaglobulinemia in patients treated with CAR-T-cell therapy: Key points for clinicians","volume":"15","author":"Kampouri","year":"2022","journal-title":"Expert. Rev. Hematol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e216","DOI":"10.1016\/S2352-3026(20)30376-8","article-title":"Chimeric antigen receptor T-cell therapy for the treatment of lymphoid malignancies: Is there an excess risk for infection?","volume":"8","author":"Gudiol","year":"2021","journal-title":"Lancet Haematol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.3324\/haematol.2020.254045","article-title":"Hematopoietic recovery and immune reconstitution after axicabtagene ciloleucel in patients with large B-cell lymphoma","volume":"106","author":"Strati","year":"2021","journal-title":"Haematologica"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Khawaja, F., Sassine, J., Handley, G., Iyer, S.P., Ramdial, J., Ahmed, S., Nieto, Y., Spallone, A., Ariza Heredia, E., and Chemaly, R.F. (2022, January 23\u201326). Herpesviruses Infections in CAR T Cell Recipients. Proceedings of the 2022 Tandem Meetings\u2014Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR, Salt Lake City, UT, USA.","DOI":"10.1016\/S2666-6367(22)00649-2"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Sassine, J., Agudelo Higuita, N.I., Siegrist, E.A., Saeedi, A., Corbisiero, M.F., Connelly, P., Bastias, A.G., Dib, R.W., Henao-Cordero, J., and Chastain, D.B. (Clin. Microbiol. Infect., 2024). Timeline and outcomes of viral and fungal infections after Chimeric Antigen Receptor (CAR) T-cell therapy: A large database analysis, Clin. Microbiol. Infect., in press.","DOI":"10.1016\/j.cmi.2024.11.008"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1111\/bjh.18828","article-title":"Real-world evidence of the safety and survival with CD19 CAR-T cell therapy for relapsed\/refractory solid organ transplant-related PTLD","volume":"202","author":"McKenna","year":"2023","journal-title":"Br. J. Haematol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/j.jtct.2024.07.018","article-title":"Best Practice Considerations by The American Society of Transplant and Cellular Therapy: Infection Prevention and Management After Chimeric Antigen Receptor T Cell Therapy for Hematological Malignancies","volume":"30","author":"Shahid","year":"2024","journal-title":"Transplant. Cell. Ther."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1136\/bjophthalmol-2021-320814","article-title":"Ocular adverse events associated with chimeric antigen receptor T-cell therapy: A case series and review","volume":"107","author":"Mumtaz","year":"2023","journal-title":"Br. J. Ophthalmol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1097\/CJI.0000000000000388","article-title":"CMV and HSV Pneumonia After Immunosuppressive Agents for Treatment of Cytokine Release Syndrome Due to Chimeric Antigen Receptor-modified T (CAR-T)-Cell Immunotherapy","volume":"44","author":"Heldman","year":"2021","journal-title":"J. Immunother."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"3590","DOI":"10.1182\/bloodadvances.2019000717","article-title":"Durable preservation of antiviral antibodies after CD19-directed chimeric antigen receptor T-cell immunotherapy","volume":"3","author":"Hill","year":"2019","journal-title":"Blood Adv."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Walti, C.S., Krantz, E.M., Maalouf, J., Boonyaratanakornkit, J., Keane-Candib, J., Joncas-Schronce, L., Stevens-Ayers, T., Dasgupta, S., Taylor, J.J., and Hirayama, A.V. (2021). Antibodies against vaccine-preventable infections after CAR-T cell therapy for B cell malignancies. JCI Insight, 6.","DOI":"10.1172\/jci.insight.146743"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1056\/NEJMoa1706640","article-title":"Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation","volume":"377","author":"Marty","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1093\/cid\/ciae321","article-title":"Consensus Definitions of Cytomegalovirus (CMV) Infection and Disease in Transplant Patients Including Resistant and Refractory CMV for Use in Clinical Trials: 2024 Update From the Transplant Associated Virus Infections Forum","volume":"79","author":"Ljungman","year":"2024","journal-title":"Clin. Infect. Dis."},{"key":"ref_20","unstructured":"Sassine, J., Khawaja, F., Shank, B.R., Lovell, A., Lee, J., DiPippo, A., Rausch, C.R., Spallone, A., Ariza Heredia, E., and Chemaly, R.F. (October, January 29). Clinically Significant CMV Infections in Patients with Lymphoma or Multiple Myeloma. Proceedings of the DWeek: Open Forum Infectious Disease, Virtual."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Cheng, J., Huang, J., Cao, W., Huang, L., Mao, X., Chen, L., Zhou, J., and Wang, N. (2023). Case Report: Fatal cytomegalovirus pneumonia after CAR-T cell therapy in the long-term follow-up. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1226148"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Meller, L., Jagadeesh, V., Wilson, K., Oca, M.C., Sestak, T., and Scott, N. (2024). Bilateral Cytomegalovirus Retinitis After Chimeric Antigen Receptor T-cell Therapy for B-cell Lymphoma. Cureus, 16.","DOI":"10.7759\/cureus.56637"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Bin Dokhi, H., Alharbi, A.O., Ibnouf, N.H., Alahmari, B., and Refka, M.N. (2022). Post-CD19 Chimeric Antigen Receptor T-Cell Therapy Cytomegalovirus Retinitis. Cureus, 14.","DOI":"10.7759\/cureus.23002"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Khawaja, F., Ahmed, S., Iyer, S.P., Sassine, J., Handley, G., Prakash, R., VanWierren, T., Jackson, J., Zubovskaia, A., and Ramdial, J. (2024). Cytomegaloviral Infections in Recipients of Chimeric Antigen Receptor T-Cell Therapy: An Observational Study With Focus on Oncologic Outcomes. Open Forum Infect. Dis., 11.","DOI":"10.1093\/ofid\/ofae422"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"3813","DOI":"10.1182\/bloodadvances.2024012922","article-title":"Incidence and outcomes of cytomegalovirus reactivation after chimeric antigen receptor T-cell therapy","volume":"8","author":"Lin","year":"2024","journal-title":"Blood Adv."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"615","DOI":"10.3324\/haematol.2022.281719","article-title":"Cytomegalovirus reactivation after CD19 CAR T-cell therapy is clinically significant","volume":"108","author":"Chen","year":"2023","journal-title":"Haematologica"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"851.e1","DOI":"10.1016\/j.jtct.2022.09.007","article-title":"Impact of Cytomegalovirus Replication in Patients with Aggressive B Cell Lymphoma Treated with Chimeric Antigen Receptor T Cell Therapy","volume":"28","author":"Iacoboni","year":"2022","journal-title":"Transplant. Cell Ther."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/j.cmi.2023.05.010","article-title":"Cytomegalovirus DNAemia in haematological patients undergoing CD19-directed chimeric antigen receptor T-cell therapy: Should it be systematically monitored?","volume":"29","author":"Hernani","year":"2023","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/ejh.13712","article-title":"Characteristics and recognition of early infections in patients treated with commercial anti-CD19 CAR-T cells","volume":"108","author":"Kikozashvili","year":"2022","journal-title":"Eur. J. Haematol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1093\/cid\/ciad708","article-title":"Cytomegalovirus (CMV) Reactivation and CMV-Specific Cell-Mediated Immunity After Chimeric Antigen Receptor T-Cell Therapy","volume":"78","author":"Kampouri","year":"2024","journal-title":"Clin. Infect. Dis."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1111\/j.1600-6143.2009.02824.x","article-title":"The \u2019indirect\u2019 effects of cytomegalovirus infection","volume":"9","author":"Freeman","year":"2009","journal-title":"Am. J. Transplant."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1093\/cid\/ciab298","article-title":"Refractory and Resistant Cytomegalovirus After Hematopoietic Cell Transplant in the Letermovir Primary Prophylaxis Era","volume":"73","author":"Sassine","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.cmi.2024.03.001","article-title":"Mortality in recipients of allogeneic haematopoietic cell transplantation in the era of cytomegalovirus primary prophylaxis: A single-centre retrospective experience","volume":"30","author":"Khawaja","year":"2024","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Handley, G., Hasbun, R., and Okhuysen, P. (2021). Human herpesvirus 6 and central nervous system disease in oncology patients: A retrospective case series and literature review. J. Clin. Virol., 136.","DOI":"10.1016\/j.jcv.2021.104740"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Li, N., Zhang, R., Wang, J., Zhu, X., Meng, F., Cao, Y., Wang, G., and Yang, Y. (2024). Case report: Acute HHV6B encephalitis\/myelitis post CAR-T cell therapy in patients with relapsed\/refractory aggressive B-cell lymphoma. Front. Neurol., 15.","DOI":"10.3389\/fneur.2024.1334000"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1056\/NEJMcps2114818","article-title":"Confused about Confusion","volume":"386","author":"Spanjaart","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.ijid.2021.09.061","article-title":"Human herpesvirus 6 myelitis after chimeric antigen receptor T-cell therapy","volume":"112","author":"Handley","year":"2021","journal-title":"Int. J. Infect. Dis."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Khawaja, F., Sassine, J., Handley, G., Prakash, R., Angelidakis, G., Ahmed, S., Ramdial, J., Nieto, Y., Rondon, G., and Ariza Heredia, E. (2023, January 15\u201319). Human Herpes Virus 6 DNAemia within 1 Year of Chimeric Antigen Receptor T Cell Therapy. Proceedings of the 2023 Tandem Meetings\u2014Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR: Tandem Meetings, Orlando, FL, USA.","DOI":"10.1016\/S2666-6367(23)00352-4"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1182\/blood.2024024145","article-title":"Human herpesvirus 6 reactivation and disease are infrequent in chimeric antigen receptor T-cell therapy recipients","volume":"144","author":"Kampouri","year":"2024","journal-title":"Blood"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Kampouri, E., Handley, G., and Hill, J.A. (2024). Human Herpes Virus-6 (HHV-6) Reactivation after Hematopoietic Cell Transplant and Chimeric Antigen Receptor (CAR)-T Cell Therapy: A Shifting Landscape. Viruses, 16.","DOI":"10.3390\/v16040498"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1038\/s41586-023-06704-2","article-title":"Latent human herpesvirus 6 is reactivated in CAR T cells","volume":"623","author":"Lareau","year":"2023","journal-title":"Nature"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1056\/NEJMoa042207","article-title":"A population-based study of primary human herpesvirus 6 infection","volume":"352","author":"Zerr","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1016\/j.cmi.2019.04.029","article-title":"Reporting infections in clinical trials of patients with haematological malignancies","volume":"25","author":"Tau","year":"2019","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1200\/JCO.22.02197","article-title":"Acknowledging Infection Risk in Bispecific Antibody Trials in the Treatment of Multiple Myeloma","volume":"41","author":"Cliff","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"3555","DOI":"10.1182\/bloodadvances.2024012916","article-title":"Infections in patients with lymphoma treated with bispecific antibodies: A systematic review and meta-analysis","volume":"8","author":"Reynolds","year":"2024","journal-title":"Blood Adv."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Longhitano, A.P., Slavin, M.A., Harrison, S.J., and Teh, B.W. (2021). Bispecific antibody therapy, its use and risks for infection: Bridging the knowledge gap. Blood Rev., 49.","DOI":"10.1016\/j.blre.2021.100810"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in Relapsed or Refractory Multiple Myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","article-title":"Elranatamab in relapsed or refractory multiple myeloma: Phase 2 MagnetisMM-3 trial results","volume":"29","author":"Lesokhin","year":"2023","journal-title":"Nat. Med."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","article-title":"Talquetamab, a T-Cell-Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma","volume":"387","author":"Chari","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1111\/ajt.12401","article-title":"What is the impact of hypogammaglobulinemia on the rate of infections and survival in solid organ transplantation? A meta-analysis","volume":"13","author":"Florescu","year":"2013","journal-title":"Am. J. Transplant."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1002\/jmv.1890360113","article-title":"Immunoglobulin G subclasses and lymphocyte stimulatory responses to cytomegalovirus in transplant patients with primary cytomegalovirus infections","volume":"36","author":"Mathiesen","year":"1992","journal-title":"J. Med. Virol."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Lejeune, M., Kose, M.C., Duray, E., Einsele, H., Beguin, Y., and Caers, J. (2020). Bispecific, T-Cell-Recruiting Antibodies in B-Cell Malignancies. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.00762"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1111\/bjh.19668","article-title":"Mitigating infection risks: The promise and challenge of bispecific antibodies in haematological malignancies","volume":"205","author":"Rafei","year":"2024","journal-title":"Br. J. Haematol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1182\/blood.2022015956","article-title":"T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals","volume":"140","author":"Philipp","year":"2022","journal-title":"Blood"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"S71","DOI":"10.1016\/j.cmi.2018.02.003","article-title":"ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: An infectious diseases perspective (Agents targeting lymphoid cells surface antigens [I]: CD19, CD20 and CD52)","volume":"24","author":"Mikulska","year":"2018","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1056\/NEJMoa2016272","article-title":"Dasatinib-Blinatumomab for Ph-Positive Acute Lymphoblastic Leukemia in Adults","volume":"383","author":"Foa","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Sanchez-Paz, L., Tirado Zambrana, P.S., Villa Poza, C., Hernandez-Rivas, J.A., and Landete Hernandez, E. (2024). Iron deficiency anemia: An early clinical presentation of cytomegalovirus-induced hemorrhagic colitis in chronic myeloid leukemia patients under dasatinib treatment. Ther. Adv. Hematol., 15.","DOI":"10.1177\/20406207241291736"},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Shahid, Z., Okwali, M., Joseph, A., Seo, S.K., Lue, J.K., Boardman, A.P., Caron, P., David, K.A., Epstein-Peterson, Z.D., and Ghione, P. (2023, January 9\u201312). Infectious Complicantions in Patients with Relapsed or Refractory (R\/R) Non-Hodgkin\u2019s Lymphoma (NHL) Treated with the Anti-CD20xCD3 Bispecific Antibody (bsAb) Mosunetuzumab. Proceedings of the 65th ASH Annual Meeting, San Diego, CA, USA.","DOI":"10.1182\/blood-2023-187911"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0140-6736(21)01338-6","article-title":"Teclistamab, a B-cell maturation antigen x CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): A multicentre, open-label, single-arm, phase 1 study","volume":"398","author":"Usmani","year":"2021","journal-title":"Lancet"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1002\/cncr.35107","article-title":"Incidence, timing, and management of infections in patients receiving teclistamab for the treatment of relapsed\/refractory multiple myeloma in the MajesTEC-1 study","volume":"130","author":"Nooka","year":"2024","journal-title":"Cancer"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1038\/s41591-023-02589-w","article-title":"Elranatamab in relapsed or refractory multiple myeloma: The MagnetisMM-1 phase 1 trial","volume":"29","author":"Bahlis","year":"2023","journal-title":"Nat. Med."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.1182\/bloodadvances.2022009435","article-title":"Risk of infections associated with the use of bispecific antibodies in multiple myeloma: A pooled analysis","volume":"7","author":"Mazahreh","year":"2023","journal-title":"Blood Adv."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Sim, B.Z., Longhitano, A., Er, J., Harrison, S.J., Slavin, M.A., and Teh, B.W. (2023). Infectious complications of bispecific antibody therapy in patients with multiple myeloma. Blood Cancer J., 13.","DOI":"10.1038\/s41408-023-00808-8"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"E349","DOI":"10.1002\/ajh.27071","article-title":"Increased risk of infection reporting with anti-BCMA bispecific monoclonal antibodies in multiple myeloma: A worldwide pharmacovigilance study","volume":"98","author":"Contejean","year":"2023","journal-title":"Am. J. Hematol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.cmi.2024.02.023","article-title":"Characteristics and incidence of infections in patients with multiple myeloma treated by bispecific antibodies: A national retrospective study","volume":"30","author":"Jourdes","year":"2024","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Nath, K., Shekarkhand, T., Nemirovsky, D., Derkach, A., Costa, B.A., Nishimura, N., Farzana, T., Rueda, C., Chung, D.J., and Landau, H.J. (2024). Comparison of infectious complications with BCMA-directed therapies in multiple myeloma. Blood Cancer J., 14.","DOI":"10.1038\/s41408-024-01043-5"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"906","DOI":"10.3324\/haematol.2023.283590","article-title":"The changing spectrum of infection with BCMA and GPRC5D targeting bispecific antibody (bsAb) therapy in patients with relapsed refractory multiple myeloma","volume":"109","author":"Hammons","year":"2024","journal-title":"Haematologica"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1158\/2643-3230.BCD-23-0049","article-title":"IVIg Use Associated with Ten-Fold Reduction of Serious Infections in Multiple Myeloma Patients Treated with Anti-BCMA Bispecific Antibodies","volume":"4","author":"Lancman","year":"2023","journal-title":"Blood Cancer Discov."},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Raje, N., Anderson, K., Einsele, H., Efebera, Y., Gay, F., Hammond, S.P., Lesokhin, A.M., Lonial, S., Ludwig, H., and Moreau, P. (2023). Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: Consensus recommendations from an expert panel. Blood Cancer J., 13.","DOI":"10.1038\/s41408-023-00879-7"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"e255","DOI":"10.1016\/S1470-2045(23)00159-6","article-title":"Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: A consensus report of the European Myeloma Network","volume":"24","author":"Ludwig","year":"2023","journal-title":"Lancet Oncol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1111\/bjh.18909","article-title":"Recommendations on prevention of infections during chimeric antigen receptor T-cell and bispecific antibody therapy in multiple myeloma","volume":"203","author":"Mohan","year":"2023","journal-title":"Br. J. Haematol."}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/17\/1\/133\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T10:31:35Z","timestamp":1759919495000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/17\/1\/133"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,18]]},"references-count":72,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1]]}},"alternative-id":["v17010133"],"URL":"https:\/\/doi.org\/10.3390\/v17010133","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,18]]}}}